Novartis agrees to spend $72 per share to acquire Avidity which is a biotechnology company currently working on RNA medicines for neuromuscular diseases. The deal values Avidity at $12 billion dollars.
Avidity has been working on developing RNA drugs that can be delivered to hard-to-reach muscle cells. The company has an AOC platform or antisense oligonucelotide conjugates and has reached late-stage testing for facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1 and Duchenne muscular dystrophy. The platform is meant to restore muscle functions and slow the progression.
Novartis said this acquisition would help "unlock multibillion-dollar opportunities" and create an "industry-leading pipeline" that can "deliver innovative, targeted and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases".
Sources:
- https://www.biopharmadive.com/news/novartis-avidity-acquire-deal-rna-drugs-neuromuscular-disease/803817/
- https://www.aviditybiosciences.com/pipeline/pipeline-overview
